ASH 2023: MPN Updates

Dec 18, 2023

Catriona Jamieson, MD, PhDMichele Nadeem-Baker

Michele Nadeem Baker is joined by Catriona Jamieson, MD, PhD

In this Answers Now replay of a live program from the 2023 American Society of Hematology Annual Meeting and Exhibition, Patient Power host Michele Nadeem Baker is joined by Catriona Jamieson, MD, PhD, UC San Diego Moores Cancer Center to update patients with myeloproliferative neoplasms (MPNs) on new treatments, including combination therapies and new regimens, and how financial toxicity can impact access.

Myeloproliferative Neoplasms

What to Do When Your PV Is Progressing

From the 2023 ASH conference, experts explain treatments now available for polycythemia vera (PV) and when a PV patient should consider a bone marrow biopsy.

Myeloproliferative Neoplasms

What to Do When Your PV Is Progressing

From the 2023 ASH conference, experts explain treatments now available for polycythemia vera (PV) and when a PV patient should consider a bone marrow biopsy.

Myeloproliferative Neoplasms

“Myleofibrosis Should Be Running For Cover”

From the 2023 ASH Annual Meeting, experts explain the latest news in combination myelofibrosis treatments and how financial toxicity impacts treatment choice.

Myeloproliferative Neoplasms

“Myleofibrosis Should Be Running For Cover”

From the 2023 ASH Annual Meeting, experts explain the latest news in combination myelofibrosis treatments and how financial toxicity impacts treatment choice.

Catriona Jamieson, MD, PhD and Michele Nadeem Baker

Myeloproliferative Neoplasms

Essential Thrombocythemia Updates and Risks

From the 2023 ASH Annual Meeting and Exhibition, experts explain updates for essential thrombocythemia and updates on both COVID-19 and secondary cancer risks.

Myeloproliferative Neoplasms

Essential Thrombocythemia Updates and Risks

From the 2023 ASH Annual Meeting and Exhibition, experts explain updates for essential thrombocythemia and updates on both COVID-19 and secondary cancer risks.